Manufacturers of Human Tissue Engineered Products (HTEPs) need to develop a very strong position paper to put an end to regulators treating so many of these products as cell therapy products and compelling manufacturers to comply with the medicinal products Directive, 2003/63/EC.
Anne Dupraz Poiseau, Executive Vice President
Responsible for the definition of the Corporate Strategy and Business Development implementation plan. Participation in the structuration of the Company to allow future growth (internal and through acquisition). Managerial and expertise responsibilities and acts as senior Advisor on Advanced Therapies Medicinal Products (ATMPs, in particular on cell and tissue based therapies), combination products (drug/device combinations) and medical devices related projects (incl. e- and m-health).